About Cardio-Phoenix
Cardio-Phoenix has developed Cardio-HART, a clinically validated AI-powered cardiac diagnostic system that transforms point-of-care cardiac assessment in primary care. The system builds on standard 12-lead ECG functionality by adding structural and functional cardiac insights traditionally only available through echocardiography in secondary care settings. Cardio-HART uses synchronized electrical, acoustic, and mechanical biosignal sensing combined with AI models to detect electrical abnormalities, structural heart disease, valvular pathology (aortic stenosis, mitral regurgitation), and all three heart failure phenotypes (HFpEF, HFmrEF, HFrEF) during a single 10-minute examination. The system provides quantified left ventricular ejection fraction (LVEF) with severity grading, achieving over 90% agreement with echocardiographic measurements. Validated across 15,000+ patients in 14 European centers, Cardio-HART demonstrates 91.2% sensitivity and 88.6% specificity for heart failure detection, reduces inconclusive ECG results by 94%, and increases confirmed diagnoses by 160% compared to standard ECG alone. The technology enables general practitioners and primary care clinicians to make more confident referral decisions, reducing unnecessary echocardiography referrals by up to 66% while identifying high-priority patients who require specialist assessment. Cardio-HART functions as both a triage and diagnostic support tool, bridging the diagnostic gap between ECG screening and echocardiography, ultimately enabling earlier clinical decision-making before symptoms escalate.
Clinical Focus
Medical conditions and clinical areas addressed by Cardio-Phoenix.
Who It Serves
Milestones & Awards
Recent Milestones
Real-world nurse-led screening pilot in Spain (2025) with 47 tests in 5 hours detecting 3 early-HF cases. Multi-center post-market study completed (2023) with 15,000+ patients. Clinical validation published in European Heart Journal - Digital Health (2024).
Awards & Recognition
Cited as exemplar of non-imaging echo-equivalent diagnostics in Journal of Practice of Cardiovascular Sciences (2024). Validation results presented at ESC-HFA 2023.
Key Partnerships
Social & Media
Follow on
Latest Updates
Cardio Phoenix Highlights Cardio-HART at MEDICA 2025 After Record Interest and 250+ Leads
Cardio-HART: The AI-Powered Evolution of the ECG for Primary Care
ECG Is Failing Us — and Guidelines Already Know It
NT-proBNP Heart Failure Diagnosis in Primary Care: Where Current Pathways Fail and How Cardio-HART Complements Them
Device-Based Heart Failure Diagnostics: Why Tools Beyond NT-proBNP Are Needed
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
AccurKardia
AI-powered platform for cardiovascular disease detection and cardiac risk assessment.
Acorai
AI platform for cardiovascular disease detection and cardiac risk assessment.
Aisap
11-50 employees
AISAP provides FDA-cleared AI-powered diagnostic algorithms embedded in an operating system for point-of-care ultrasound (POCUS) devices. The platform enables rapid, expert-level cardiac imaging interpretation at the bedside, helping physicians detect structural heart disease early and make faster clinical decisions across hospitals, clinics, and screening programs.
AliveCor
AliveCor develops FDA-cleared, AI-powered ECG devices and software platforms for cardiac monitoring. The company offers portable ECG solutions ranging from consumer personal devices to clinical-grade 12-lead systems, serving patients, healthcare providers, biopharma companies, and health systems with remote and connected cardiac care.
Anumana AI
series c · 175 employees
Anumana AI develops and delivers AI-driven ECG algorithms to enable early diagnosis and intervention for cardiovascular conditions.
Artrya
11-50 employees
Artrya develops AI-powered solutions for rapid assessment of chest pain patients in emergency and primary care settings. The company's technology analyzes coronary computed tomography angiography (CCTA) to detect arterial plaque and stratify patient risk within minutes.
Bay Labs
Bay Labs is a health AI company focused on cardiology and cardiovascular health. The company's website is currently under construction with limited public information available.
BunkerHill Health
Bunkerhill Health provides Carebricks, an AI-powered platform that enables health systems to design, deploy, and operationalize AI agents across clinical and operational workflows. The platform reasons across patient data and automates actions within existing EHR systems.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.